- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT06023862
Háromágú, randomizált II. fázisú vizsgálat a dostarlimabról önmagában vagy bevacizumabbal a nem platina kemoterápiával szemben visszatérő nőgyógyászati tiszta sejtes karcinómában: DOVE (APGOT-ov7/ENGOT-ov80 vizsgálat) (DOVE)
Háromágú, randomizált II. fázisú vizsgálat a dostarlimabról önmagában vagy bevacizumabbal a nem platina kemoterápiával szemben visszatérő nőgyógyászati tiszta sejtes karcinómában: DOVE (APGOT-OV07/ENGOT-OV80 vizsgálat)
Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma.
198 subjects will be enrolled in this study and will be assigned to three groups in a 1:1:1 ratio.
-
Group A: Dostarlimab monotherapy
- First 3 cycles: Dostalimab 500mg every 3 weeks, IV
- 4 cycles ~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV
-
Group B: Dostarlimab + Bevacizumab combination therapy
- First 3 cycles: Dostalimab 500mg every 3 weeks, IV
- 4 cycles ~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV
- Bevacizumab administered IV at 15 mg/kg every 3 weeks until disease progression or unacceptable toxicity
-
Group C: General chemotherapy (one of Pegylated liposomal doxorubicin, Doxorubicin, Paclitaxel, and Gemcitabine)
A tanulmány áttekintése
Állapot
Körülmények
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 2. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
Clayton Rd.
-
Clayton, Clayton Rd., Ausztrália
- Monash Medical Centre
-
-
Edith Saint
-
Waratah, Edith Saint, Ausztrália
- Calvary Mater Newcastle
-
-
Grattan Saint
-
Melbourne, Grattan Saint, Ausztrália
- Peter MacCallum Cancer Centre
-
-
-
-
-
Goyang-si, Dél -Korea
- National Cancer Center
-
Seongnam-si, Dél -Korea
- Bundang Seoul National University Hospital
-
Seoul, Dél -Korea
- Asan Medical Center
-
Seoul, Dél -Korea
- Korea University Guro Hospital
-
Seoul, Dél -Korea
- Samsung Medical Center
-
Seoul, Dél -Korea
- Seoul National University
-
-
Seoul
-
Seoul, Seoul, Dél -Korea, 03722
- Severance Hospital, Yonsei Health System
-
-
-
-
Monkton
-
London, Monkton, Egyesült Királyság
- Guy's and St Thomas' NHS Foundation Trust
-
-
-
-
Pok Fu Ram
-
Hong Kong, Pok Fu Ram, Hong Kong
- University of Hong Kong
-
-
-
-
Fukuoka
-
Kurume, Fukuoka, Japán, 830-0011
- Kurume University Hospital
-
-
Fukushima
-
Fukushima, Fukushima, Japán, 960-1295
- Fukushima Medical University Hospital
-
-
Mie-ken
-
Tsu, Mie-ken, Japán, 514-8507
- Mie University Hospital
-
-
Miyagi
-
Sendai, Miyagi, Japán, 980-8574
- Tohoku University Hospital
-
-
Niigata
-
Niigata, Niigata, Japán, 951-8566
- Niigata Cancer Center Hospital
-
-
Saitama
-
Hidaka, Saitama, Japán, 1397-1
- Saitama Medical University International Medical Center
-
-
Tokushima
-
Tokushima, Tokushima, Japán, 770-8501
- Tokushima University Hospital
-
-
Tokyo
-
Tokyo, Tokyo, Japán, 105-0003
- The Jikei University Hospital
-
Tokyo, Tokyo, Japán, 135-8550
- The Cancer Institute Hospital Of JFCR
-
-
ㅊ Ibaraki
-
Tsukuba, ㅊ Ibaraki, Japán, 305-8576
- University of Tsukuba Hospital
-
-
-
-
-
Singapore, Szingapúr
- National University Hospital
-
-
Kent Ridge Rd
-
Singapore, Kent Ridge Rd, Szingapúr
- National University Hospital
-
-
-
-
Beitou District
-
Taipei, Beitou District, Tajvan
- Taipei Veterans General Hospital
-
-
Songshan District
-
Taipei, Songshan District, Tajvan
- Chang Gung Memorial Hospital
-
-
Zhongzheng
-
Taipei, Zhongzheng, Tajvan
- National Taiwan University Hospital
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
[Inclusion Criteria]
-
Female patient is at least 18 years of age,
-
Patient has signed the Informed Consent (ICF) and is able to comply with protocol requirements.
-
Patient with histologically proven confirmed recurrent or persistent clear cell carcinoma of the ovary, endometrium, cervix, vagina, and vulva
-
Local review by gynecologic pathologist required
-≥50% clear cell histology in case of mixed carcinoma
-
WT-1 neg (Only in case of ovarian cancer) Note: In the case of including non-ovarian clear cell carcinoma with more than 20 cases, the decision is made through discussion with the SPONSOR.
-
-
Patient with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
-
Disease progression within 12 months of completing platinum-based chemotherapy
-
1-5 prior lines of therapies Notes: Patients can participate in the trial regardless of prior exposure to bevacizumab. The sponsor may limit the enrollment of patients with prior exposure to bevacizumab in order to ensure an appropriate representativeness (approximately 50%) of patients without prior exposure to bevacizumab.
-
Patient with measurable disease according RECIST 1.1 criteria
-
Availability of Tumor tissue for translational research .
-A formalin-fixed paraffin-embedded (FFPE) tumor block(preferred) or at least 23 slides (unstained, freshly cut, serial sections) must be submitted.
-
Patients who consent to fresh tumor biopsies
-Confirmed with at least one lesion with location accessible to safely biopsy per the clinical judgement of the investigator Note: If mandatory biopsies cannot be performed as per investigator's clinical judgement, discussion and agreement between investigator and Sponsor are required.
-
Patient has adequate organ function, defined as follows:
- Absolute neutrophil count ≥ 1,500 cells/μL
- Platelets ≥ 100,000 cells/μL
- Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L
- Serum creatinine ≤ 1.5× upper limit of normal (ULN) or calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault equation for patients with creatinine levels > 1.5× institutional ULN
- Total bilirubin ≤ 1.5× ULN (≤ 2.0 x ULN in patients with known Gilbert's syndrome) or direct bilirubin ≤ 1× ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN unless liver metastases are present, in which case they must be ≤ 5× ULN
- International normalized ratio or prothrombin time (PT) ≤1.5× ULN and activated partial thromboplastin time ≤1.5× ULN.Participants taking anticoagulants may be included on a stable dose with a therapeutic INR <3.5. .
-
Patient must have a negative serum pregnancy test within 72 hours of the first dose of study medication, unless they are of non-childbearing potential. If a negative result cannot be confirmed by a urine test, a serum pregnancy test is required. Non-childbearing potential is defined as follows:
-
Patient is ≥ 45 years of age and has not had menses for > 1 year.
-
A follicle-stimulating hormone value in the postmenopausal range upon screening evaluation if amenorrhoeic for < 2 years without a hysterectomy and oophorectomy.
-
Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation:
- Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, MRI, or CT scan.
- Tubal ligation must be confirmed with medical records of the actual procedure.
- Information must be captured appropriately within the site's source documents.
-
-
Patient of childbearing potential must agree to use a highly effective method of contraception with their partners starting from time of consent through 180 days after the last dose of study treatment.
Note: Abstinence is acceptable if this is the established and preferred contraception for the patient (Information must be captured appropriately within the site's source documents).
[Exclusion Criteria]
Patients are to be excluded from the study if they meet any of the following criteria:
-
Patient has had ≥ 6 prior lines of chemotherapy. Surgery of the recurrence is allowed.
-
Patient has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
-
Patient has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy) within 21 days or < 5 times the half-life of the most recent therapy prior to Study Day 1, whichever is shorter.
Note: Palliative radiation therapy to a small field ≥ 1 week prior to Day 1 of study treatment may be allowed after discussion with the SPONSOR.
-
Patient with contraindication to chemotherapy or immune checkpoint inhibitor treatments or anti-angiogenic inhibitor
-
Patients with uncontrolled hypertension (defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥100 mmHg) based on an average of ≥ 3 BP readings on ≥ 2 sessions.
-
Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
-
Patients with current abdominal/pelvic fistula
-
Patient has a concomitant malignancy, or patient has a prior non-gynecological malignancy who has been disease-free for < 3 years or who received any active treatment in the last 3 years for that malignancy. Non-melanoma skin cancer is allowed.
-
Patient has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.
Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of disease progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability.
-
Patient has a known history of human immunodeficiency virus (HIV; HIV ½ antibodies). Participants with known human immunodeficiency virus(HIV) are allowed if they meet all of the following criteria:
- Cluster of differentiation 4(CD4) ≥350/μL and viral load <50 copies/mL.
- No history of acquired immunodeficiency syndrome-defining opportunistic infections within 12 months before enrollment.
- No history of HIV-associated malignancy for the past 5 years.
- Concurrent antiretroviral therapy as per the most current National Institutes of Health (NIH) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV started >4 weeks before study enrollment.
-
Patient with presence of hepatitis B surface antigen or a positive hepatitis C antibody test result at screening or within 3 months before first dose of dostarlimab treatment.
- Participants who are hepatitis B surface antigen positive may be enrolled if their HBV-DNA level is below the institutional lower limit.
- Participants with chronic hepatitis B virus (HBV) infection who meet the criteria for anti-HBV therapy may be eligible if the participant is on a suppressive antiviral therapy before initiation of cancer therapy.
- Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled only if a confirmatory negative hepatitis C RNA polymerase chain reaction is obtained. Hepatitis C participants may be eligible if they both have completed curative therapy and have a hepatitis C viral load <quantifiable limit.
-
Patient has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic therapy (e.g., thyroid hormone or insulin).
-
Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of systemic immunosuppressive therapy within 7 days prior to the first dose of study treatment. Patients who have received acute and/or low-dose systemic immunosuppressive medications (e.g., a one-time dose of dexamethasone for nausea or chronic use of ≤ 10 mg/day of prednisone or dose equivalent corticosteroid) may be enrolled in the study after discussion with and approval by the Sponsor. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed.
-
Patient has not recovered (to Grade ≤ 1) from previous anti-cancer therapy-induced adverse events (AEs).
Note: Patients with Grade ≤ 2 neuropathy, Grade ≤ 2 alopecia, or Grade ≤ 2 fatigue are an exception to this criterion and may qualify for the study.
-
Patient has not recovered adequately from AEs or complications from any major surgery prior to starting therapy. Major surgical procedures, other than for diagnosis, within 4 weeks prior to initiation of study treatment
-
Patient has a known hypersensitivity to bevacizumab or dostarlimab components or excipients.
-
Patient is currently participating and receiving study treatment or has participated in a study of an investigational agent and received study treatment or used an investigational device within 4 weeks of the first dose of treatment.
-
Patient is considered a poor medical condition due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent).
-
Patients with known history of non-infectious pneumonitis that required steroids or has current pneumonitis
-
Use of any of the following immunomodulatory agents within 28 days prior to the first dose of study drug:
- Interferons
- Interleukins
- Live vaccine Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. mRNA and adenoviral-based COVID-19 vaccines are considered non-live and are not exclusionary. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed as other killed vaccines, if done at least 2 weeks prior the first dose of study drug; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
-
Patient who are pregnant or lactating, or plan to become pregnant or lactate during the expected duration of the study, from screening through 180 days after the last dose of study drug.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Group A
Dostarlimab monotherapy |
Intravenous (IV) infusion
Más nevek:
|
|
Kísérleti: Group B
Dostarlimab + Bevacizumab combination therapy |
Intravenous (IV) infusion Intravenous (IV) infusion
Más nevek:
|
|
Aktív összehasonlító: Group C
General chemotherapy (one of Pegylated liposomal doxorubicin, Doxorubicin, Paclitaxel, and Gemcitabine) |
Intravenous (IV) infusion Intravenous (IV) infusion Intravenous (IV) infusion Intravenous (IV) infusion |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Progression Free Survival
Időkeret: Up to approximately 48 months
|
The time from the date of randomization until first documentation of disease progression, as determined by investigator assessment based on RECIST 1.1, or death due to any cause, whichever occurs first. |
Up to approximately 48 months
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Objective Response Rate
Időkeret: Up to approximately 48 months
|
the proportion of patients who have best overall response of either complete response (CR) or partial response (PR), as investigator assessment based on RECIST 1.1 |
Up to approximately 48 months
|
|
Disease control rate
Időkeret: Up to approximately 48 months
|
the proportion of patients who have best overall response of CR, PR, or stable disease (SD) by investigator assessment per RECIST 1.1 . SD must be achieved at ≥ 7 weeks after randomization to be considered best overall response. |
Up to approximately 48 months
|
|
Clinical benefit rate
Időkeret: Up to approximately 48 months
|
the proportion of patients who have best overall response of CR, PR, or stable disease (SD) by investigator assessment per RECIST 1.1 . (duration of SD ≥ 23 weeks after randomization) |
Up to approximately 48 months
|
|
Progression Free Survival 2
Időkeret: Up to approximately 72 months
|
the time from initial randomization to the second objective disease progression (ie, after the first subsequent therapy) or death. |
Up to approximately 72 months
|
|
Overall survival
Időkeret: Up to approximately 72 months
|
the time from the date of randomization until death due to any cause |
Up to approximately 72 months
|
|
Duration of Response Rate
Időkeret: Up to approximately 48 months
|
Measured from the time of initial response until documented tumor progression. |
Up to approximately 48 months
|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Időkeret: Up to approximately 72 months
|
Assessed by CTCAE v5.0 (by investigators). |
Up to approximately 72 months
|
|
Time to first and second Subsequent Treatment
Időkeret: Up to approximately 72 months
|
the time from the date of randomization to date of the first and second subsequent anticancer therapy or death. |
Up to approximately 72 months
|
|
Response rate of subsequent therapies
Időkeret: Up to approximately 72 months
|
the proportion of patients who have best overall response of either complete response (CR) or partial response (PR), as investigator assessment based on RECIST 1.1 |
Up to approximately 72 months
|
Egyéb eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Disease-related or Treatment-related Biomarkers
Időkeret: At the end of study, Up to approximately 72 months
|
Translational research including NGS as well as MMRd, MSI-H, PD1/L1, TMB, Immune signature, and Tie-2. |
At the end of study, Up to approximately 72 months
|
|
Comparison of RECIST1.1 and i-RECIST assessment
Időkeret: Throughout duration of study, Up to 48 months
|
By comparing RECIST 1.1 and iRECIST, evaluate the accuracy of iRECIST for assessing the therapeutic efficacy of ICIs. |
Throughout duration of study, Up to 48 months
|
Együttműködők és nyomozók
Szponzor
Együttműködők
Nyomozók
- Kutatásvezető: JUNGYUN LEE, Ph.D., Severance Hospital, Yonsei University Health System
Publikációk és hasznos linkek
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
- Urogenitális betegségek
- Nemi szervek betegségei
- Endokrin rendszer betegségei
- Urogenitális neoplazmák
- Neoplazmák webhelyenként
- Neoplazmák
- Női urogenitális betegségek
- Női urogenitális betegségek és terhességi szövődmények
- Neoplazmák szövettani típus szerint
- Méhbetegségek
- Nemi szervek betegségei, nő
- Endokrin mirigy neoplazmák
- Neoplazmák, mirigyes és epiteliális
- Adenokarcinóma
- Petefészek betegségek
- Adnexális betegségek
- Nemi szervek daganatai, nők
- Gonád rendellenességek
- Karcinóma
- A méhnyak betegségei
- Méh neoplazmák
- Vulva betegségek
- Hüvelyi betegségek
- Petefészek neoplazmák
- A méhnyak neoplazmái
- Endometrium neoplazmák
- Vulva neoplazmák
- Adenocarcinoma, tiszta sejt
- Hüvelyi neoplazmák
- Aminosavak, peptidek és fehérjék
- Fehérjék
- Szerves vegyi anyagok
- Heterociklusos vegyületek, 1 gyűrű
- Heterociklusos vegyületek
- Szénhidrogének
- Cikloparaffinok
- Szénhidrogének, aliciklusos
- Szénhidrogének, ciklikus
- Terpének
- Szénhidrátok
- Policiklusos aromás szénhidrogének
- Szénhidrogének, aromás
- Policiklusos vegyületek
- Glikozidok
- Antitestek, monoklonális, humanizált
- Antitestek, monoklonális
- Antitestek
- Immunoglobulinok
- Immunoproteinek
- Vérfehérjék
- Szérumglobulinok
- Globulinok
- Taxoidok
- Ciklodekánok
- Diterpének
- Deoxi -cytidin
- Citidin
- Pirimidin nukleozidok
- Pirimidinek
- Antraciklinok
- Nafthacének
- Aminoglikozidok
- Daunorubicin
- Bevacizumab
- Gemcitabine
- Doxorubicin
- Paclitaxel
- liposzómális doxorubicin
- dostarlimab
Egyéb vizsgálati azonosító számok
- 4-2023-0794
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .